Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab Dosing with Paclitaxel in Gastric/GEJ Cancer
NCT02514551Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Primary completion
- Oct 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Eli Lilly and Company. Started Oct 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02514551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514551.